Cardiovascular Systems (Cardiovascular Systems) Debt-to-Equity : 0.09 (As of Dec. 2022)

View and export this data going back to 2006. Start your Free Trial

What is Cardiovascular Systems Debt-to-Equity?

Cardiovascular Systems's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was $0.0 Mil. Cardiovascular Systems's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was $21.2 Mil. Cardiovascular Systems's Total Stockholders Equity for the quarter that ended in Dec. 2022 was $239.4 Mil. Cardiovascular Systems's debt to equity for the quarter that ended in Dec. 2022 was 0.09.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Cardiovascular Systems's Debt-to-Equity or its related term are showing as below:

CSII' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.03 Med: 0.16 Max: 1.77
Current: 0.09

During the past 13 years, the highest Debt-to-Equity Ratio of Cardiovascular Systems was 1.77. The lowest was -0.03. And the median was 0.16.

CSII's Debt-to-Equity is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 0.21 vs CSII: 0.09

Cardiovascular Systems Debt-to-Equity Historical Data

The historical data trend for Cardiovascular Systems's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardiovascular Systems Debt-to-Equity Chart

Cardiovascular Systems Annual Data

Trend

Jun13

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Debt-to-Equity

Get a 7-Day Free Trial

0.16

0.14

0.08

0.09

Cardiovascular Systems Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Debt-to-Equity	Get a 7-Day Free Trial															0.09	0.09	0.09	0.09	0.09

Competitive Comparison of Cardiovascular Systems's Debt-to-Equity

For the Medical Devices subindustry, Cardiovascular Systems's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cardiovascular Systems's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cardiovascular Systems's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Cardiovascular Systems's Debt-to-Equity falls into.

Cardiovascular Systems Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Cardiovascular Systems's Debt to Equity Ratio for the fiscal year that ended in Jun. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	21.624)	/	249.48
	=	0.09

Cardiovascular Systems's Debt to Equity Ratio for the quarter that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	21.231)	/	239.389
	=	0.09

Cardiovascular Systems (NAS:CSII) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Cardiovascular Systems Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Cardiovascular Systems's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Cardiovascular Systems (Cardiovascular Systems) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cardiovascular Systems Inc (NAS:CSII) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

1225 Old Highway 8 Northwest, Saint Paul, MN, USA, 55112-6416

Website

https://www.csi360.com

Cardiovascular Systems Inc is a medical technology company focused on patients with peripheral and coronary artery diseases. Its peripheral artery disease systems are catheter-based platforms used to treat plaque in leg arteries above and below the knee. The firm's orbital atherectomy systems are used in peripheral and coronary commercial applications. Its OAS products include the Diamondback 360 Peripheral and Stealth 360 systems. Sales of Peripheral OAS contribute the majority of revenue. Cardiovascular systems generate the vast majority of its revenue in the United States.

Executives

Jeffrey S. Points	officer: Chief Financial Officer	C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Scott R Ward	director	RAYMOND HOLDINGS, LLC, 6410 BALLANTINE CT., INVER GROVE HEIGHTS MN 55077
Erik Paulsen	director	C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Rhonda J. Robb	officer: Chief Operating Officer	C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Martha Goldberg Aronson	director	40 WEST HIGHLAND PARK DRIVE NE, HUTCHINSON MN 55350
Sachin H. Jain	director	C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Alexander Rosenstein	officer: General Counsel & Corp. Secy	C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Sandra Sedo	officer: Chief Compliance Officer	C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Kelvin K. Womack	director	C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Stephen J. Rempe	officer: Chief Human Resources Officer	C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
John M. Hastings	officer: VP Manufacturing & Operations	C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Stephen Stenbeck	director	C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Ryan Egeland	officer: VP of Medical Affairs	C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
David Whitescarver	officer: VP of Corp. Dev. & IP	C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Laura Gillund	officer: Chief Talent Officer